País: Canadá
Língua: inglês
Origem: Health Canada
GRANISETRON (GRANISETRON HYDROCHLORIDE)
SANDOZ CANADA INCORPORATED
A04AA02
GRANISETRON
1MG
SOLUTION
GRANISETRON (GRANISETRON HYDROCHLORIDE) 1MG
INTRAVENOUS
1ML/3ML
Prescription
5-HT3 RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0123183001; AHFS:
CANCELLED POST MARKET
2019-08-01
_Granisetron Hydrochloride Injection SDZ _ _Page 1 of 25 _ PRODUCT MONOGRAPH PR GRANISETRON HYDROCHLORIDE INJECTION SDZ PRESERVATIVE FREE Solution for Injection 1 mg/mL granisetron (as granisetron hydrochloride) 1 mL and 3 mL ampoules Manufacture’s Standard STERILE ANTIEMETIC (5-HT 3 RECEPTOR ANTAGONIST) Sandoz Canada Inc. Date of Revision: October 23, 2014 145 Jules-Léger Boucherville, QC, Canada J4B 7K8 Submission Control No: 177134 _Granisetron Hydrochloride Injection SDZ _ _Page 2 of 25 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................................. 3 INDICATIONS AND CLINICAL USE ...................................................................................... 3 CONTRAINDICATIONS ........................................................................................................... 3 WARNINGS AND PRECAUTIONS .......................................................................................... 4 ADVERSE REACTIONS ............................................................................................................ 6 DRUG INTERACTIONS ............................................................................................................ 8 DOSAGE AND ADMINISTRATION ........................................................................................ 9 OVERDOSAGE ........................................................................................................................ 10 ACTION AND CLINICAL PHARMACOLOGY ..................................................................... 10 STORAGE AND STABILITY .................................................................................................. 12 DOSAGE FORMS, COMPOSITION AND PACKAGING ...................................................... 13 PART II: SCIENTIFIC INFORMATION ................................................................................ 1 Leia o documento completo